Neuronetics (STIM) Q2 2025: Greenbrook Drives 132% Revenue Surge, Margin Mix Shifts Shape Profit Path

2025-08-05 | By EarningsIQ Research

Neuronetics’ Q2 results underscore the transformative impact of the Greenbrook integration, with clinic revenue now the company’s primary growth engine and operational improvements accelerating cash flow progress. The quarter brought both record clinic performance and a recalibration of margin expectations as the revenue mix shifts toward lower-margin services, while strategic focus sharpens on referral-driven growth and operational discipline for sustainable profitability into 2026.

Summary

• Greenbrook Integration Unlocks Scale: Clinic revenue now dominates, validating the acquisition’s growth thesis.
• Operational Focus on Cash Flow: Accelerated collections and cost controls improve cash burn and set up positive cash flow targets.
• Margin Structure in Transition: Lower-margin clinic and Spravato mix prompts new margin guidance and sharper profitability focus.

Performance Analysis

Neuronetics delivered a pivotal quarter, with total revenue up 132% year-over-year to $38.1 million, driven by the full inclusion of Greenbrook, clinic-based mental health centers acquired to expand the company’s reach and recurring revenue. Greenbrook clinic revenue accounted for $23 million, marking its highest ever and now comprising about 60% of the total business, a structural shift from the legacy NeuroStar device and treatment segment. NeuroStar system revenue was $3.5 million, with 41 systems shipped and average selling price (ASP) holding above $85,000, signaling continued competitive strength in the capital equipment market for transcranial magnetic stimulation (TMS) systems.

Gross margin compressed to 48.6% from 74% last year, reflecting the larger share of clinic revenue and the expansion of Spravato, a ketamine-based therapy, under a buy and bill reimbursement model that carries lower margin but broader patient access. Operating expenses rose 25% to $25.8 million, largely from Greenbrook’s G&A, though sales and marketing efficiencies partially offset the increase. Cash used in operations improved to $3.5 million, ahead of plan and a marked step toward the company’s goal of cash flow breakeven in Q3 and positive in Q4 2025.

• Clinic Revenue Now Core Driver: Greenbrook’s $23 million in Q2 revenue makes it the largest and fastest-growing segment.
• Gross Margin Compression: Mix shift to clinics and Spravato buy and bill meaningfully reduced company-wide margins, resetting expectations.
• Cash Flow Execution: Process improvements in claims and collections cut cash burn, supporting the path to operational break-even.

Legacy device and treatment growth remains positive at 13% YoY on a pro forma basis, but the company’s future is increasingly tied to its ability to scale and optimize the integrated clinic platform and manage the evolving margin profile.

Executive Commentary

Strategic Positioning

1. Greenbrook Integration as Growth Catalyst

The Greenbrook acquisition, a network of TMS clinics, has shifted Neuronetics’ business model toward recurring, clinic-driven revenue with higher patient throughput and referral leverage. Clinic revenue now accounts for the majority of total revenue, confirming the rationale for the deal and creating a vertically integrated platform that can scale both treatments and new therapy rollouts.

2. Margin Management Amid Mix Shift

The rapid expansion of clinic and Spravato buy and bill revenue, while driving top-line growth, has diluted gross margin. Management is now more selective in rolling out the buy and bill model, focusing only on sites and payers where reimbursement supports incremental gross profit dollars, not just percent margins. This discipline is crucial as the company balances access and profitability in a complex reimbursement environment.

3. Provider Connection Program and Referral Focus

Neuronetics is pivoting its marketing toward direct provider education, especially targeting primary care and non-psychiatric physicians, to drive high-conversion referrals to both Greenbrook clinics and Better Me Provider (BMP) sites. Early data shows that provider referrals are 10 times more likely to convert to treatment than traditional marketing leads, and BMP sites treat three times as many patients per site per quarter as non-BMP practices. This strategy aims to maximize marketing ROI and patient acquisition efficiency.

4. Operational Efficiency and Cash Flow Discipline

Cost controls, automation (such as kiosk check-in), and a renewed focus on claims processing have accelerated cash collections and reduced legacy AR. The company is also restructuring its operations team to identify further cost savings and optimize clinic throughput, supporting the drive toward positive cash flow and sustainable margin improvement.

5. Adolescent Market Expansion

Insurance coverage and real-world data are enabling rapid growth in adolescent patient starts, with a 25% increase in the first half of 2025. Neuronetics is leveraging its TrackStar outcomes database to support clinical adoption and payer engagement, positioning the company to capture a larger share of this underserved market segment.

Key Considerations

This quarter marks a structural pivot for Neuronetics, with the Greenbrook acquisition redefining revenue composition, operational priorities, and strategic risk factors. Investors must recalibrate expectations for gross margin, cash flow trajectory, and the sources of future growth.

Key Considerations:

• Clinic Mix Now Dominant: Greenbrook’s recurring revenue base is now the largest contributor, reducing legacy device volatility but compressing gross margin.
• Spravato Model Complexity: Buy and bill expansion is being throttled to ensure only margin-accretive growth, reflecting learning curve realities in payer reimbursement.
• Marketing Reallocation: Provider Connection Program is shifting spend from broad marketing to high-efficiency, referral-driven education, with early signs of superior patient conversion.
• Cash Flow Inflection: Operational improvements and new funding from Perceptive Advisors increase liquidity and reduce risk of near-term cash shortfall.
• Adolescent Growth Opportunity: Expanded insurance coverage and clinical validation support a new patient segment with high unmet need.

Risks

Gross margin pressure from the clinic-heavy revenue mix and variable Spravato reimbursement could persist longer than expected, particularly if payer dynamics or operational integration delays limit the pace of margin recovery. The company’s path to cash flow positivity depends on continued execution in claims collections, cost controls, and disciplined growth, while competitive pressures in TMS devices and mental health services remain elevated. Any disruption in payer relationships or regulatory shifts could materially impact revenue and profitability.

Forward Outlook

For Q3 2025, Neuronetics guided to:

• Net revenue of $37 million to $39 million

For full-year 2025, management maintained guidance:

• Total revenue of $149 million to $155 million
• Gross margin of 48% to 50% (down from prior 55%)
• Operating expenses of $100 million to $105 million

Management expects cash flow from operations to reach breakeven in Q3 and turn positive in Q4, driven by ongoing margin optimization, operational improvements, and careful Spravato rollout. Year-end cash is projected at $25 million to $28 million, benefiting from recent debt funding.

Takeaways

Neuronetics’ Q2 results confirm the Greenbrook acquisition as a transformative catalyst, but also highlight the new margin and operational realities of a clinic-centric model. Investors should track the pace of margin recovery, provider referral conversion, and cash flow inflection as the primary signals of sustainable value creation.

• Clinic Revenue is Now the Growth Engine: The shift to recurring, clinic-driven revenue brings scale but compresses margins, necessitating new operational discipline.
• Margin Recovery Hinges on Mix and Execution: Careful management of Spravato expansion and operational efficiency will determine the trajectory of profitability.
• Referral Strategy is Key to Sustainable Growth: Provider Connection Program and BMP expansion are central to future patient volume and marketing efficiency.

Conclusion

Neuronetics’ Q2 marks a decisive pivot to a vertically integrated, clinic-led business with greater revenue scale, but also new margin and execution challenges. The company’s ability to optimize its revenue mix, accelerate cash collections, and leverage provider-driven growth will define its path to sustainable profitability heading into 2026.

Industry Read-Through

The Neuronetics-Greenbrook integration provides a real-time case study for mental health and device companies seeking to blend capital equipment with recurring clinic revenue, highlighting both the scale advantages and the gross margin tradeoffs inherent in such models. The Spravato rollout also illustrates the complexity of buy and bill reimbursement in mental health, a challenge for any therapy provider seeking to expand access through direct payer billing. Finally, the success of referral-driven marketing and adolescent patient expansion signals that targeted provider engagement and data-backed clinical validation are emerging as key levers for growth across behavioral health and medtech sectors.

STIM Healthcare Mental Health Clinic Operations Gross Margin Spravato Referral Marketing Adolescent Care